Literature DB >> 28813559

Coverage of Intravenous Immunoglobulin for Autoimmune Blistering Diseases Among US Insurers.

Manuel Valdebran1, Kyle T Amber1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28813559      PMCID： PMC5817455          DOI： 10.1001/jamadermatol.2017.2614

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  5 in total

1.  Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States.

Authors:  Romi Bloom; Kyle T Amber
Journal:  J Am Acad Dermatol       Date:  2015-08       Impact factor: 11.527

2.  A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid.

Authors:  Masayuki Amagai; Shigaku Ikeda; Takashi Hashimoto; Masato Mizuashi; Akihiro Fujisawa; Hironobu Ihn; Yasushi Matsuzaki; Mikio Ohtsuka; Hiroshi Fujiwara; Junichi Furuta; Osamu Tago; Jun Yamagami; Akiko Tanikawa; Hisashi Uhara; Akimichi Morita; Gen Nakanishi; Mamori Tani; Yumi Aoyama; Eiichi Makino; Masahiko Muto; Motomu Manabe; Takayuki Konno; Satoru Murata; Seiichi Izaki; Hideaki Watanabe; Yukie Yamaguchi; Setsuko Matsukura; Mariko Seishima; Koji Habe; Yuichi Yoshida; Sakae Kaneko; Hajime Shindo; Kimiko Nakajima; Takuro Kanekura; Kenzo Takahashi; Yasuo Kitajima; Koji Hashimoto
Journal:  J Dermatol Sci       Date:  2016-11-09       Impact factor: 4.563

3.  Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.

Authors:  Yassine J Daoud; Ketan G Amin
Journal:  Int Immunopharmacol       Date:  2005-12-05       Impact factor: 4.932

4.  A randomized double-blind trial of intravenous immunoglobulin for pemphigus.

Authors:  Masayuki Amagai; Shigaku Ikeda; Hiroshi Shimizu; Hajime Iizuka; Katsumi Hanada; Setsuya Aiba; Fumio Kaneko; Seiichi Izaki; Kunihiko Tamaki; Zenro Ikezawa; Masahiro Takigawa; Mariko Seishima; Toshihiro Tanaka; Yoshiki Miyachi; Ichiro Katayama; Yuji Horiguchi; Sachiko Miyagawa; Fukumi Furukawa; Keiji Iwatsuki; Michihiro Hide; Yoshiki Tokura; Masutaka Furue; Takashi Hashimoto; Hironobu Ihn; Sakuhei Fujiwara; Takeji Nishikawa; Hideoki Ogawa; Yasuo Kitajima; Koji Hashimoto
Journal:  J Am Acad Dermatol       Date:  2009-04       Impact factor: 11.527

5.  Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling.

Authors:  Grace Wang; Mary S Beattie; Ninez A Ponce; Kathryn A Phillips
Journal:  Genet Med       Date:  2011-12       Impact factor: 8.822
  5 in total
  1 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.